Biostax Corp. (BTAX)

Market Cap	10.71K -100.0%
Revenue (ttm)	n/a
Net Income	-1.87M
EPS	-0.02
Shares Out	107.11M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,194
Average Volume	24,528
Open	0.0001
Previous Close	0.0001
Day's Range	0.0001 - 0.0001
52-Week Range	0.0001 - 0.0002
Beta	0.78
RSI	28.84
Earnings Date	Apr 13, 2026

About Biostax

Biostax Corp. operates as a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology products. Its lead investigational drug candidate Lodonal, an once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Its programs also include Global Telehealth platform; Medtech asset, an early development stage program that uses blockchain and smart contracts to manage and secure prescriptions and electronic health records; JKB-122,...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Noreen Griffin
• Employees: 4
• Stock Exchange: OTCMKTS
• Ticker Symbol: BTAX